Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net income (loss)	$ (1,702,024)	$ 1,464,930
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Net loss contributed from noncontrolling interest	(5,472)
Depreciation expense	17,380	18,176
Amortization of patents	78,458	77,947
Common stock and options issued for compensation, consulting, and vendor services	1,031,623	1,077,213
Bad debt reversal		(308,350)
Gain on Dilutive Effect on Medical Joint Venture		(1,363,650)
Changes in operating assets and liabilities:
(Increase) Decrease in accounts receivable	(8,623)	(126,323)
(Increase) Decrease in inventories	(1,175,447)	(683,091)
Decrease to advances on contracts	1,587,155	519,094
Decrease to prepaid expenses and other current assets	(304,114)	88,610
(Increase) in other assets	(1,768)	(5,600)
(Decrease) in accounts payable	(516,460)	(316,226)
Increase (Decrease) in accrued expenses	466,035	(116,275)
Net cash provided by (used in) operating activities	376,943	1,258,736
Cash flows from investing activities:
Investment in Medical Joint Venture	(856,105)	(484,828)
Purchases of property and equipment	(82,210)	(5,539)
Payments for patent rights	(16,752)	(21,020)
Net cash used in investing activities	(1,304,528)	(561,387)
Cash flows from financing activities:
Proceeds from exercise of stock options	348,697	34,600
Proceeds from the sale of common stock		200,000
Capital Contribution from noncontrolling interest	400,000
Net proceeds on Private Placement Offering	9,449,683
Proceeds from related party loan		50,000
Net cash provided by financing activities	10,148,380	284,600
NET INCREASE IN CASH AND CASH EQUIVALENTS	9,220,795	981,949
Cash and cash equivalents at beginning of year	1,147,198	165,249
Cash and cash equivalents at end of year	10,367,993	1,147,198
Supplemental disclosure of non cash investing and financing activities:
Shares issued to directors for the exercise of stock options	41,250	34,600
Shares issued to directors for compensation	55,200	45,000
Shares issued for conversion of notes payable and accrued interest		860,081
Shares issued to employees for exercise of stock options	250,531
Shares issued to employees in lieu of cash compensation	69,041	47,500
Shares issued to consultants for services	274,500	400,000
Shares issued to consultants for exercise of stock options	56,916
Capital Contribution-Fixed Asset, net for Medical Joint Venture	21,584
Gain on Dilutive Effect on Medical Joint Venture		1,363,650
Medical Joint Venture
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Loss on Earnings from joint venture	891,500	924,363
Education Joint Venture
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Loss on Earnings from joint venture	17,890	7,918
Cash flows from investing activities:
Investment in Joint Venture		(50,000)
Milestone China
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Loss on Earnings from joint venture	810
Cash flows from investing activities:
Investment in Joint Venture	$ (349,461)